Advertisement
BAX vs BDX
Which Stock Would AI Choose? Baxter International Inc. (BAX) vs. Becton, Dickinson and Company (BDX) Stock Comparison
Key Takeaways
- Baxter International Inc. (BAX) delivered stronger recent momentum following its second-quarter 2026 earnings, with shares rising sharply after an upward revision to full-year guidance.
- Becton, Dickinson and Company (BDX) reported solid revenue growth and an earnings beat in its fiscal second quarter but has experienced more muted price action amid broader sector pressures.
- Both companies operate in the medical technology sector, with BAX showing higher recent volatility and BDX demonstrating steadier, longer-term stability in its product portfolio.
- Relative performance highlights a contrast in growth catalysts: BAX benefited from broad-based segment gains, while BDX emphasized drug delivery and diagnostics demand.
- Market sentiment has favored BAX in recent weeks due to clearer positive catalysts, whereas BDX trades at a discount to recent highs with focus on operational execution.
Introduction
Medical technology stocks Baxter International Inc. (BAX) and Becton, Dickinson and Company (BDX) offer investors exposure to essential healthcare products and devices. This comparison examines their recent performance, business drivers, and positioning within the broader medtech landscape. Institutional investors, portfolio managers, and traders evaluating sector allocation or relative value opportunities in healthcare may find this analysis relevant for understanding competitive dynamics and market responses in the current environment.
BAX Overview and Recent Performance
Baxter International Inc. (BAX) is a global medtech company focused on renal care, medication delivery, and other hospital products. In recent market activity, the stock experienced significant upward movement following its second-quarter 2026 earnings release. Reported sales reached $2.96 billion, reflecting 5% growth, while the company raised its full-year 2026 sales and earnings outlook. This development contributed to improved investor sentiment and notable price appreciation in the ensuing period, with shares trading around the mid-$20 range amid heightened trading volume.
BDX Overview and Recent Performance
Becton, Dickinson and Company (BDX) provides medical devices, diagnostics, and life science solutions, with emphasis on drug delivery systems and specimen management. The company reported fiscal second-quarter 2026 results showing revenue of $4.71 billion, a 5.2% increase, along with an adjusted earnings per share beat. Although the stock has consolidated below prior peaks amid sector rotation, management raised its full-year profit forecast on sustained demand in key segments. Price behavior in recent weeks has reflected measured responses to operational updates rather than sharp directional shifts.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top-performing AI trading bots from a pool of hundreds that cover thousands of tickers across various markets. Only those demonstrating the strongest alignment with prevailing conditions, consistent risk-adjusted returns, and robust statistical profiles earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and ticker sets, with performance metrics, win rates, and drawdown statistics varying widely to suit different risk tolerances. Review the curated selection on the Trending AI Robots page for detailed profiles and live signals.
Head-to-Head Comparison
In business model terms, BAX maintains a broader hospital-focused portfolio with emphasis on renal and acute care, while BDX concentrates on integrated diagnostics and drug delivery platforms. Growth drivers differ as BAX highlighted across-the-board segment expansion in its latest results, contrasting with BDX’s targeted strength in high-demand device categories. Recent momentum favors BAX following its guidance upgrade and associated price surge, whereas BDX shows resilience but trades at a wider discount to 52-week highs. Risk factors include execution on integration for both, with BDX carrying additional exposure to reimbursement dynamics in diagnostics. Sector exposure remains comparable within healthcare equipment, though market sentiment has tilted toward the more immediate positive catalysts evident in BAX’s recent activity.
Tickeron AI Verdict
Based on observable trend consistency, the magnitude of recent positive catalysts, and relative price stability following earnings, Tickeron’s AI models currently assign a probabilistic edge to Baxter International Inc. (BAX) over Becton, Dickinson and Company (BDX). This assessment reflects stronger short-term momentum alignment and clearer upward revisions in forward guidance, though outcomes remain subject to evolving market conditions and sector-wide developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a Hold and BDX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 2 FA rating(s) are green whileBDX’s FA Score has 2 green FA rating(s).
- BAX’s FA Score: 2 green, 3 red.
- BDX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 5 TA indicator(s) are bullish while BDX’s TA Score has 5 bullish TA indicator(s).
- BAX’s TA Score: 5 bullish, 4 bearish.
- BDX’s TA Score: 5 bullish, 4 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а -2.98% price change this week, while BDX (@Pharmaceuticals: Other) price change was +3.70% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.26%. For the same industry, the average monthly price growth was +8.63%, and the average quarterly price growth was +6.97%.
Reported Earning Dates
BAX is expected to report earnings on Oct 29, 2026.
BDX is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.26% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BAX | BDX | BAX / BDX | |
| Capitalization | 13.8B | 50B | 28% |
| EBITDA | 762M | 4.97B | 15% |
| Gain YTD | 40.016 | 21.791 | 184% |
| P/E Ratio | 87.85 | 31.73 | 277% |
| Revenue | 11.5B | 22.2B | 52% |
| Total Cash | 2.15B | N/A | - |
| Total Debt | 9.67B | 17.3B | 56% |
BAX | BDX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 7 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 89 | |
SMR RATING 1..100 | 96 | 86 | |
PRICE GROWTH RATING 1..100 | 5 | 14 | |
P/E GROWTH RATING 1..100 | 33 | 62 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (7) in the Medical Specialties industry is significantly better than the same rating for BAX (92). This means that BDX’s stock grew significantly faster than BAX’s over the last 12 months.
BDX's Profit vs Risk Rating (89) in the Medical Specialties industry is in the same range as BAX (100). This means that BDX’s stock grew similarly to BAX’s over the last 12 months.
BDX's SMR Rating (86) in the Medical Specialties industry is in the same range as BAX (96). This means that BDX’s stock grew similarly to BAX’s over the last 12 months.
BAX's Price Growth Rating (5) in the Medical Specialties industry is in the same range as BDX (14). This means that BAX’s stock grew similarly to BDX’s over the last 12 months.
BAX's P/E Growth Rating (33) in the Medical Specialties industry is in the same range as BDX (62). This means that BAX’s stock grew similarly to BDX’s over the last 12 months.
| BAX | BDX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 58% | 1 day ago 61% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 46% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 50% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 51% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 47% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 50% |
| Advances ODDS (%) | 12 days ago 57% | 4 days ago 44% |
| Declines ODDS (%) | 4 days ago 65% | 24 days ago 43% |
| BollingerBands ODDS (%) | 1 day ago 52% | 1 day ago 50% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 51% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +0.79% | ||
| COO - BDX | 54% Loosely correlated | -0.56% | ||
| BAX - BDX | 51% Loosely correlated | -1.18% | ||
| TMO - BDX | 50% Loosely correlated | -1.28% | ||
| CNMD - BDX | 48% Loosely correlated | +1.18% | ||
| SOLV - BDX | 47% Loosely correlated | +2.46% | ||
More | ||||